The Calmette-Guérin (BCG) Vaccine: Is it a better choice for the treatment of viral warts?

OBJECTIVES

This study aimed to compare the effectiveness of the Calmette-Guérin (BCG) vaccine with topical salicylic acid (SA) in the treatment of viral warts.

METHODS

This non-randomised controlled trial was conducted at the Al-Sader Teaching Hospital, Basrah, Iraq, from January 2016 to April 2017. A total of 201 patients with viral warts were injected with an intradermal purified protein derivative. Subsequently, those with negative tuberculin test results received an intradermal BCG vaccination, while those with positive results underwent conventional treatment with topical SA. Patients were assessed for any signs of improvement at one, two and three months.

RESULTS

Overall, 190 patients completed the trial; of these, 133 (70%) received the BCG vaccine and 57 (30%) were treated with topical SA. Complete response to treatment was observed in 9.8% and 5.3% of patients in the BCG and SA groups, respectively ( <0.001). Cure rates were significantly higher for patients with genital (22.2% versus 7.7%; = 0.002) and common warts (8.5% versus 0%; = 0.001) treated with the BCG vaccine; however, the reverse was true for flat warts (12.9% versus 25%; = 0.041). A binary logistic regression analysis indicated that BCG therapy was the only significant independent predictor of positive treatment response (odds ratio: 7.56, 95% confidence interval: 3.72-15.36; <0.001).

CONCLUSION

The BCG vaccine was more effective than topical SA for treating viral warts, with the best response noted in the treatment of genital warts, followed by flat warts. However, warts demonstrated least response to this treatment.